StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) KPIs and segments

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$168.98−1.28 (-0.75%)

Close on Nov 18, 2026Market cap $209.59BP/E –Yield 1.87%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Gilead Sciences · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)

Nhìn nhanh KPI của Gilead Sciences: 40 chỉ số vận hành, trong đó có Total revenues, Consolidated revenues — United States và Total HIV Franchise Product Sales, lấy từ 188 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Product sales($M)3
8,2897,6276,9467,9027,3457,0546,6137,5367,5156,9126,6477,070
United States($M)
6,3615,6014,9265,8735,2745,0384,6315,5505,4334,9164,6095,181
Europe($M)
1,0581,1551,1371,2221,1441,1781,0731,1601,1541,1181,1441,128
Rest of World($M)
869872883809928838909826928878894762
Biktarvy($M)3
4,0593,7723,3613,9683,6863,5303,1503,7743,4723,2322,9463,109
United States($M)
3,2842,9812,5733,2552,9402,7992,4743,1292,8262,5852,3152,588
Europe($M)
442468437445427429375399375370365333
Rest of World($M)
333323352268320302301246272277265188
Descovy($M)3
1,046967807819701653586617586485426510
United States($M)
998921761768652601538563534434371457
Rest of World($M)
262323242528272828262928
Europe($M)
222323262324212524252625
Intangible asset Trodelvy($M)3
506457402384357364293355332320309299
United States($M)
336307253251221224181247226224206226
Europe($M)
989295888996757780696848
Rest of World($M)
715754454744373126263624
Genvoya($M)3
339289264380377377364470449440403516
United States($M)
301236215331323322305410384372332447
Europe($M)
273733343440404244454948
Rest of World($M)
121616151916191821232122
Vemlidy($M)3
333289237287280252252260232243225217
United States($M)
1701249114913612210014812611795115
Rest of World($M)
1511521321251321171401009511511992
Europe($M)
131313131213121111111110
Yeztugo($M)3
30523216639150
United States($M)
29422315839150
Rest of World($M)
1097000
Europe($M)
000000
Yescarta($M)3
294346332368349393386389387414380
United States($M)
114132120151123162160160145186170
Europe($M)
107139146143151154149157182169158
Rest of World($M)
7375677575777772605852
Odefsey($M)3
286239221310277298281336326315310339
United States($M)
226171153239206221215252248233223258
Europe($M)
525859626166577369727671
Rest of World($M)
810910101110119101111
Sofosbuvir/Velpatasvir($M)3
274303283276309342346330385476405378
United States($M)
139142141139146184166185222267248216
Rest of World($M)
7680827197769975961267889
Europe($M)
598160656581806967847973
Livdelzi($M)3
2031671331057840
United States($M)
176147115937440
Europe($M)
2620181140
Rest of World($M)
100000
Symtuza - Revenue share($M)3
132138138133124124114144139168141
United States($M)
10310510798958882112103131104
Europe($M)
2630283226332929333433
Rest of World($M)
33333333333
Other Liver Disease($M)3
11711811450412612312113011611310796
Europe($M)
6279781127072765454474738
United States($M)
3920153763933285845474239
Rest of World($M)
161921171719171817191919
AmBisome($M)3
99110138118123129139109130151144111
Europe($M)
524759666965676671697068
Rest of World($M)
445972465256663652656039
United States($M)
34752757617144
Veklury($M)3
8623144211277121302338692214555719
United States($M)
6314112801405119910839376315365
Europe($M)
122146743192280815370181
Rest of World($M)
117186593508215021985169175
Other HIV($M)3
82567324473929111210010511780
United States($M)
5523362084350506765656046
Europe($M)
222427242233313326254525
Rest of World($M)
510912891012915129
Other($M)3
6851588661737075711308090
United States($M)
362239523444475247985964
Rest of World($M)
252111262021141616241217
Europe($M)
888978988899
Tecartus($M)3
60707590839278989810710098
Europe($M)
313437513541313629373627
United States($M)
242930314041405363635566
Rest of World($M)
588789896784
Royalty, contract and other revenues($M)3
11176142242427543330413944
Europe($M)
616981441110111513151537
Rest of World($M)
346454621113
United States($M)
220371337161725235
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)8
United States($M)
6,3635,6034,9265,8765,2815,0514,6685,5675,4504,9414,6335,185
Europe($M)
1,0651,3241,1441,2361,5551,1891,0841,1751,1671,1331,1591,164
Rest of World($M)
872876889813933842915826929879894765
Total revenues ($M)($M)3
7,8036,9607,9257,7697,0826,6677,5697,5456,9546,6867,114
Total revenues YoY growth (%)(%)
10.0%4.0%5.0%3.0%2.0%6.0%7.0%5.0%5.0%-4.0%
Total product sales ($M)($M)5
7,6276,9467,9027,3457,0546,6137,5367,5156,9126,6477,070
Total product sales excluding Veklury (Base business, $M)($M)1
7,6046,8027,6917,0686,9346,3117,1986,8236,6986,0926,350
Product sales ex-Veklury YoY growth (%)(%)
10.0%8.0%7.0%4.0%4.0%4.0%13.0%7.0%6.0%6.0%-24.0%
Total product sales — U.S. ($M)($M)
5,6014,9265,8735,2745,0384,6315,5505,4334,9164,6095,181
Total product sales — Europe ($M)($M)
1,1551,1371,2221,1441,1781,0731,1601,1541,1181,1441,128
Total product sales — Rest of World ($M)($M)
872883809928838909826928878894762
Total product sales YoY growth (%)(%)
8.0%5.0%5.0%-2.0%2.0%-1.0%7.0%7.0%5.0%5.0%-4.0%
Royalty, contract and other revenues ($M)($M)4
176142242427543330413944
Royalty, contract and other revenues — U.S. ($M)($M)
20371337161725235
Royalty, contract and other revenues — Europe ($M)($M)
16981441110111513151537
Royalty, contract and other revenues — Rest of World ($M)($M)
46454621113
Royalty, contract and other revenues YoY growth (%)(%)
-75.0%-35.0%-34.0%37.0%-26.0%-46.0%18.0%-15.0%-21.0%
Total HIV Franchise Product Sales ($M)($M)4
5,6935,0305,8005,2775,0884,5875,4525,0734,7454,3424,693
Total HIV Franchise Product Sales — U.S. sales ($M)($M)
4,6594,0044,8454,2994,0963,6644,5324,1613,8213,4053,899
Total HIV Franchise Product Sales — Europe sales ($M)($M)
640607623592624553602570571596534
Total HIV Franchise Product Sales — Rest of World sales ($M)($M)
393419332386368370317342353342261
Total HIV Franchise Product Sales — Worldwide YoY growth (%)(%)
12.0%10.0%6.0%4.0%7.0%6.0%16.0%9.0%3.0%4.0%-2.0%
Total Liver Disease Franchise Product Sales ($M)($M)6
877767845819795758719733832737691
Total Liver Disease Franchise Product Sales — U.S. sales ($M)($M)
433362457414413335391393431385370
Total Liver Disease Franchise Product Sales — Europe sales ($M)($M)
193170175158170168134132142137121
Total Liver Disease Franchise Product Sales — Rest of World sales ($M)($M)
251235213247211256194207259215200
Total Liver Disease Franchise Product Sales — Worldwide YoY growth (%)(%)
10.0%1.0%17.0%12.0%-4.0%3.0%4.0%4.0%17.0%9.0%-1.0%
Total HCV Franchise (legacy sub-franchise breakout) ($M)($M)3
432
Total HCV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M)
251
Total HCV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M)
84
Total HCV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M)
97
Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M)($M)3
259
Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)($M)
119
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)($M)
37
Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)($M)
103
Veklury (remdesivir — COVID-19 antiviral) ($M)($M)1
23144211277121302338692214555719
Veklury (remdesivir — COVID-19 antiviral) — Worldwide YoY growth (%)(%)
-81.0%-52.0%-37.0%-60.0%-44.0%-45.0%-53.0%9.0%-16.0%-3.0%-28.0%
Total Oncology Franchise Product Sales ($M)($M)5
873810841788849757843816841789765
Total Oncology Franchise Product Sales — U.S. sales ($M)($M)
468403434384427381460433474431479
Total Oncology Franchise Product Sales — Europe sales ($M)($M)
265278281275291255270291275262215
Total Oncology Franchise Product Sales — Rest of World sales ($M)($M)
14012912712913112111392929671
Total Oncology Franchise Product Sales — Worldwide YoY growth (%)(%)
3.0%7.0%4.0%-3.0%1.0%-4.0%10.0%6.0%15.0%18.0%24.0%
Total Kite Cell Therapy Product Sales ($M)($M)3
417407458432485464488485521480467
Total Kite Cell Therapy Product Sales — U.S. sales ($M)($M)
161150182163203200213208250225253
Total Kite Cell Therapy Product Sales — Europe sales ($M)($M)
173183193186196180193211206195167
Total Kite Cell Therapy Product Sales — Rest of World sales ($M)($M)
8374828386848266666047
Total Other Products Sales ($M)($M)4
161196205184202209184201280224201
Total Other Products Sales — U.S. sales ($M)($M)
26465736525258531157368
Total Other Products Sales — Europe sales ($M)($M)
5567757673767480777977
Total Other Products Sales — Rest of World sales ($M)($M)
8083727277815268887156
Other Products (Cayston, Jyseleca, Letairis, Zydelig) ($M)($M)1
51588661737075711308090
Other Products (Cayston, Jyseleca, Letairis, Zydelig) — Worldwide YoY growth (%)(%)
-20.0%-6.0%11.0%-8.0%-28.0%-7.0%-8.0%-7.0%15.0%13.0%-20.0%
Accrued rebates and chargebacks liability (Balance Sheet, $M)($M)
4,2334,1184,3374,9314,2154,1853,8924,1133,9234,2633,802
GAAP Research and development (R&D) expenses ($M)($M)3
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,408
R&D by cost type — Personnel, infrastructure and other support costs ($M)($M)
1,146861911807855854954808830963823
R&D by cost type — Clinical studies and outside services / other costs ($M)($M)
618510673539636524687587520557585
Non-GAAP Research and development expenses ($M)($M)1
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,408
Non-GAAP R&D expenses as % of total revenues (%)(%)
22.6%19.7%20.0%17.3%21.1%20.7%21.7%18.5%19.4%22.7%19.8%
Acquired in-process research and development (IPR&D) expenses ($M)($M)1
11,18310753917061253-11505384,131347
In-process research and development (IPR&D) impairment charges ($M)($M)
12,04310753917061253-11505384,131347
Equity method & fair value option biotech investments carrying value ($M)($M)3
295308393393369359386382376359340
Equity method investment in Arcus Biosciences, Inc. — Fair value carrying amount ($M)($M)
969679749427448
Equity method investment in Galapagos NV / Lakefront Biotherapeutics NV — Fair value carrying amount ($M)($M)
500504551570462
Other equity method investments (incl. Assembly Biosciences) — Fair value carrying amount ($M)($M)
17115518314353
Strategic Oncology Affiliate — Arcus Biosciences (NYSE: RCUS) Total Revenues ($M)($M)7
337116882371110-49
Arcus revenue from Gilead — Other collaboration revenue ($M)($M)
25546888711109
Arcus total other collaboration revenue ($M)($M)
25546888711109
Arcus revenue from Gilead — License & development services (legacy axis, $M)($M)
81015220
Arcus Biosciences — Total operating expenses ($M)($M)2
137151147168168150129153145161122
Arcus Biosciences — Research and development (R&D) expense ($M)($M)
11312212114113912210112311510993
Arcus Biosciences — General and administrative (G&A) expense ($M)($M)
2429262729282830303229
Arcus Biosciences — Operating income (loss) ($M)($M)
-96-134-114-142-8-122-103-105-106-16-91
Arcus Biosciences — Net income (loss) ($M)($M)2
-91-128-106-1350-112-94-92-93-4-81
Arcus Biosciences — Diluted EPS ($/sh)($)
-0.72-1.02-1.270-1.14-1-1.02-0.05
Arcus Biosciences — Diluted weighted-average shares (M shares)
12612541071079819191860
Arcus Biosciences — Total assets ($M)($M)6
9249971,1399741,0751,1561,1501,2521,1861,2931,095
Arcus Biosciences — Cash and cash equivalents ($M)($M)
150201222238248192150201156185127
Arcus Biosciences — Marketable securities, current ($M)($M)
552621759593663805828888813810632
Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M)($M)
363111115152016283538
Arcus Biosciences — Deferred collaboration revenue, current ($M)($M)
1934355271728510511312491
Arcus Biosciences — Deferred collaboration revenue, noncurrent ($M)($M)
3745435360219234289214242307
Arcus Biosciences — Total current liabilities ($M)($M)
198209231235210192226215199204184
Non-GAAP product gross margin (%)(%)4
79.3%79.2%79.5%78.6%78.7%76.7%79.0%79.1%77.7%76.6%70.4%
GAAP product gross margin (%)(%)
79.3%79.2%79.5%78.6%78.7%76.7%79.0%79.1%77.7%76.6%70.4%
Non-GAAP cost of goods sold ($M)($M)
1,5791,4451,6231,5691,5011,5401,5811,5741,5441,5522,090
GAAP cost of goods sold ($M)($M)
1,5791,4451,6231,5691,5011,5401,5811,5741,5441,5522,090
Non-GAAP COGS adjustments (Acquired intangible amortization & step-up, $M)($M)
5795765795775795795795795795791,110
Non-GAAP operating margin (%)(%)3
-133.2%37.2%25.0%42.8%34.9%33.6%32.4%11.8%38.0%-64.6%22.7%
GAAP operating margin (%)(%)
-133.2%37.2%25.0%42.8%34.9%33.6%32.4%11.8%38.0%-64.6%22.7%
Non-GAAP operating income (loss) ($M)($M)
-10,3942,5861,9843,9212,4742,2372,4513,2583,265-4,3221,612
Non-GAAP selling, general and administrative (SG&A) expenses ($M)($M)2
1,9211,4511,7941,3571,3651,2581,9061,4331,3771,3751,608
Non-GAAP SG&A expenses as % of total revenues (%)(%)
24.6%20.9%22.6%17.5%19.3%18.9%25.2%19.0%19.8%20.6%22.6%
Non-GAAP SG&A adjustments ($M)($M)
4008810657365428268011
Non-GAAP net income (loss) attributable to Gilead ($M)($M)4
-10,4962,0212,1833,0951,9601,3151,7832,5312,519-4,1701,417
Non-GAAP diluted earnings (loss) per share ($/sh)($)
-8.451.611.862.471.561.041.902.022.01-1.321.72
Non-GAAP effective tax rate (%)(%)
-2.4%21.7%-5.0%16.2%19.3%20.2%17.8%-31.1%21.4%7.0%14.3%
GAAP effective tax rate (%)(%)
-2.4%21.7%-5.0%16.2%19.3%20.2%17.8%-31.1%21.4%7.0%14.3%
Total non-GAAP adjustments before income taxes ($M)($M)6
2,7225398521126751,0827892,1131,0123,219938
Total non-GAAP adjustments to costs and expenses ($M)($M)
3,0656811,1045948176566632,3706203,2051,127
Non-GAAP R&D adjustments ($M)($M)
3351719124140291316117-44
Non-GAAP other income (expense) adjustments (equity securities fair value, $M)($M)
-343-142-252-483-142426126-25839214-189
Income tax effect of non-GAAP adjustments ($M)($M)
-574-58-252-79-162-154-152-521-168-732-218
Discrete and related tax charges (benefits) ($M)($M)
44-46454-11-48-4229314-60-39-12
Total non-GAAP adjustments after tax ($M)($M)
2,105528146435609706071,2789052,526732
Non-GAAP Free cash flow (Form 8-K Selected Cash Flow Information, $M)($M)2
3,4322,4273,1213,9627201,6532,8284,1691,1952,1141,954
Operating cash flow (Form 8-K Selected Cash Flow Information, $M)($M)
3,5732,5443,3264,1098271,7572,9754,3091,3252,2192,168
Capital expenditures (Form 8-K Selected Cash Flow Information, $M)($M)
140117205147107104147140130105214
Total inventories (Current + Noncurrent, $M)($M)5
4,2984,3394,3684,3873,9133,7783,5893,4353,3883,3633,366
Inventories — Raw materials ($M)($M)
1,4151,3571,4141,3961,2711,1961,2951,3321,2591,2371,246
Inventories — Work in process ($M)($M)
1,1631,2761,3061,3411,0391,076847684803778847
Inventories — Finished goods ($M)($M)
1,7191,7061,6471,6501,6031,5061,4471,4191,3261,3481,272
Inventories — Current portion (Balance Sheet, $M)($M)
1,9531,9141,7741,7851,8251,7591,7101,8692,0261,8531,787
Inventories — Noncurrent portion (included in Other long-term assets, $M)($M)
2,3452,4242,5942,6022,0872,0181,8791,5661,3621,5101,578
Property, plant and equipment, net ($M)($M)2
5,8335,6385,6065,5005,4595,4215,4145,3915,3465,3215,317
Property, plant and equipment, gross ($M)($M)
8,7078,4228,3028,1938,0807,9637,8847,766
Accumulated depreciation ($M)($M)
2,8742,7842,6962,6932,6212,5422,4702,449
Intangible assets, net ($M)($M)3
14,03216,38216,97817,97018,56619,35519,94820,54622,83223,42826,454
Goodwill ($M)($M)
8,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,314
Finite-lived intangible assets, net ($M)($M)7
14,03214,08214,67815,27015,86616,46517,05817,65618,19218,78819,384
Finite-lived intangible assets, gross ($M)($M)
32,41331,86331,88831,88431,88431,88431,87931,87931,81931,81931,819
Finite-lived intangible assets — Accumulated amortization ($M)($M)
18,38217,78217,21116,61416,01915,42114,82214,22413,62813,03212,436
Trodelvy (sacituzumab govitecan) intangible asset — Net carrying value ($M)($M)2
7,0267,2967,5667,8368,1078,3778,6478,9179,1879,4589,728
Trodelvy intangible asset — Gross ($M)($M)
11,73011,73011,73011,73011,73011,73011,73011,73011,73011,73011,730
Trodelvy intangible asset — Accumulated amortization ($M)($M)
4,7044,4344,1643,8943,6233,3533,0832,8132,5432,2722,002
Sofosbuvir (Epclusa / Harvoni / Vosevi) intangible asset — Net carrying value ($M)($M)2
1,9232,0972,2722,4472,6222,7972,9713,1463,3213,4963,670
Sofosbuvir intangible asset — Gross ($M)($M)
10,72010,72010,72010,72010,72010,72010,72010,72010,72010,72010,720
Sofosbuvir intangible asset — Accumulated amortization ($M)($M)
8,7978,6238,4488,2738,0987,9237,7497,5747,3997,2247,050
Yescarta (axicabtagene ciloleucel) intangible asset — Net carrying value ($M)($M)2
3,7803,8813,9834,0844,1864,2884,3894,4914,5934,6944,796
Yescarta intangible asset — Gross ($M)($M)
7,1107,1107,1107,1107,1107,1107,1107,1107,1107,1107,110
Yescarta intangible asset — Accumulated amortization ($M)($M)
3,3303,2293,1273,0262,9242,8222,7212,6192,5172,4162,314
Hepcludex (bulevirtide) intangible asset — Net carrying value ($M)($M)2
933408430451473494516537559580602
Hepcludex intangible asset — Gross ($M)($M)
1,395845845845845845845845845845845
Hepcludex intangible asset — Accumulated amortization ($M)($M)
462437415394372351329308286265243
Other finite-lived intangible assets — Net carrying value ($M)($M)2
372400428451479510535565533560588
Other finite-lived intangible assets — Gross ($M)($M)
1,4581,4581,4831,4791,4791,4791,4741,4741,4141,4141,414
Other finite-lived intangible assets — Accumulated amortization ($M)($M)
1,0871,0591,0561,0281,001971940911883855827
Indefinite-lived IPR&D intangible assets ($M)($M)1
02,3002,3002,7002,7002,8902,8902,8904,6404,6407,070
Indefinite-lived IPR&D — Trodelvy NSCLC (impaired in FY2024, $M)($M)
1,7501,7501,7501,7501,8001,7501,8005,900
Level 3 contingent consideration liabilities ($M)($M)1
60275278274271216206222208222228
Contingent consideration liability — MYR GmbH / Hepcludex ($M)($M)
60275278274271216206222208222228
Litigation accrual reserve (Antitrust, patent & product liability, $M)($M)
000002202420
Restructuring expenses — Total ($M)($M)3
17403714137476282163
Restructuring expenses — Research and development ($M)($M)
141686383051350
Restructuring expenses — Selling, general and administrative ($M)($M)
251757364623813
Accrued restructuring liability ($M)($M)
607361529213893
Long-term debt, noncurrent carrying value ($M)($M)3
23,83220,86122,12922,13522,14022,14624,89621,43721,54021,52723,189
Current portion of long-term debt and senior notes ($M)($M)
2,4141,3132,8072,8062,8062,8061,8151,8121,8093,6671,798
Total debt carrying value ($M)($M)
26,24622,17424,93724,94124,94624,95226,71023,24923,34925,19324,987
Total long-term debt fair value ($M)($M)
22,26219,17822,34222,39821,98121,88623,33520,93119,84121,93022,567
Cash dividends declared per share ($/sh)($)3
0.820.820.790.790.790.770.770.77
Common stock repurchases — Cash paid ($M)($M)
355419230435527730350300100400150
Common stock repurchases — Value retired ($M)($M)
355419230435527730350300100400150
Common stock repurchases — Shares repurchased (M shares)
33245734252
Total stock-based compensation (SBC) expense ($M)($M)
231218230230225209222216210187201
Income tax expense (benefit) ($M)($M)
242559-105589468334385-297438-315237
Global employees headcount (people)1
Deferred compensation plan rabbi trust assets & liabilities ($M)($M)
458405406401374340343343327318284
U.S. PPI: Pharmaceutical Preparation Manufacturing (Index Dec 2009=100)1
U.S. PCE: Pharmaceutical and Other Medical Products ($B SAAR)
3,790.303,699.903,667.003,614.803,529.803,464.703,417.803,358.203,288.203,244.403,159.40
Income Statement — Total revenues ($M)($M)10
7,8036,9607,9257,7697,0826,6677,5697,5456,9546,6867,114
Cost of goods sold ($M)($M)
1,5791,4451,6241,5691,5011,5401,5811,5741,5441,5522,090
Research and development expenses ($M)($M)
1,7641,3721,5841,3461,4911,3791,6411,3951,3511,5201,408
Selling, general and administrative expenses ($M)($M)
1,9211,4511,7941,3571,3651,2581,9071,4331,3771,3751,608
Operating income (loss) ($M)($M)
-10,3942,5861,9843,3272,4742,2372,4528882,644-4,3221,612
Interest expense ($M)($M)
247240255256254260249238237254252
Income (loss) before income taxes ($M)($M)
-10,2542,5802,0783,6412,4291,6492,1679562,053-4,4861,653
Income tax expense (benefit) ($M)($M)
242559-105589468334385-297438-315237
Net income (loss) attributable to Gilead ($M)($M)
-10,4962,0212,1833,0521,9601,3151,7831,2531,614-4,1701,429
Diluted earnings (loss) per share ($/sh)($)
-8.451.612.431.561.0411.29-3.34
Diluted weighted-average shares (M shares)
1,2431,2541,2541,2551,2591,2541,2511,247
Balance Sheet — Total assets ($M)($M)10
49,36256,27859,02358,53355,72156,43458,99554,52553,57956,29262,125
Accounts receivable, net ($M)($M)
5,0554,7414,9135,0954,7814,3884,4204,5874,6634,6694,660
Inventories ($M)($M)
1,9531,9141,7741,7851,8251,7591,7101,8692,0261,8531,787
Total current assets ($M)($M)
13,94518,64118,34217,87414,71816,90119,17314,77912,31714,04116,085
Property, plant and equipment, net ($M)($M)
5,8335,6385,6065,5005,4595,4215,4145,3915,3465,3215,317
Goodwill ($M)($M)
8,3148,3148,3148,3148,3148,3148,3148,3148,3148,3148,314
Intangible assets, net ($M)($M)
14,03216,38216,97817,97018,56619,35519,94820,54622,83223,42826,454
Total current liabilities ($M)($M)
11,0209,47611,81312,29811,18912,34412,00411,72510,78113,01511,280
Long-term debt, noncurrent ($M)($M)
23,83220,86122,12922,13522,14022,14624,89621,43721,54021,52723,189
Retained earnings ($M)($M)
2,20014,13113,73012,82511,32510,93111,49711,07311,16510,65616,304
Total stockholders' equity ($M)($M)
11,74423,43122,61821,45619,59019,07819,24618,39018,19717,45522,749
Cash Flow Statement — Operating cash flow ($M)($M)3
3,5732,5443,3274,1088271,7572,9754,3091,3252,2192,169
Capital expenditures ($M)($M)
140117205147107104147141130105215
Cash dividends paid ($M)($M)
1,0291,0409941,0059941,010973983972990943
Repurchases of common stock ($M)($M)
355419230435527730350300100400150

59 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Fiscal calendar: Gilead Sciences, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026). Gilead operates as a single global biopharmaceutical operating segment (Note 16), so commercial performance is tracked across Therapeutic Area franchises (HIV, Liver Disease, Veklury, Oncology / Cell Therapy & Trodelvy, Other Products) and 2-dimensional Brand × Geography (Worldwide, U.S., Europe, Rest of World) product sales.
  • Core commercial, GTN & R&D KPIs (Groups 1–7) cover: (1) Consolidated Revenues ($7,805M in Q2 2026 / $29,440M in FY25), Total Product Sales ($7,629M in Q2 2026 / $28,913M in FY25 across U.S. $5,574M, Europe $1,226M, Rest of World $829M in Q2 2026), Base Business Product Sales excluding Veklury ($7,606M in Q2 2026, +11% YoY / $28,001M in FY25), Royalty/Contract revenues ($176M in Q2 2026 / $527M in FY25), and foreign currency sales share (25% in Q2 2026 / 26% in FY25); (2) HIV Franchise ($5,747M in Q2 2026, +12% YoY / $20,785M in FY25: Biktarvy $3,772M, Descovy $967M, Genvoya $392M, Odefsey $291M, Symtuza revenue share $145M, Yeztugo twice-yearly PrEP injectable $169M in Q2 2026, plus legacy Truvada/Stribild/Complera/Atripla, Biktarvy U.S. HIV treatment share & U.S. PrEP market volume growth); (3) Liver Disease Franchise ($877M in Q2 2026, +10% YoY / $3,172M in FY25: Sofosbuvir/Velpatasvir Epclusa $351M, Vemlidy $276M, Livdelzi PBC launch $167M, Other Liver $83M, plus historical HCV/HBV/HDV breakouts) and Veklury ($23M in Q2 2026 / $911M in FY25); (4) Oncology Franchise ($874M in Q2 2026, +4% YoY / $3,294M in FY25: Kite Cell Therapy $417M [Yescarta $344M, Tecartus $73M] and Trodelvy ADC $457M) & Other Products ($107M in Q2 2026: AmBisome $66M, Other $41M); (5) Gross-to-Net (GTN) deductions ($19,953M or 41% of gross product sales in FY25), 13-year Rebates & Chargebacks rollforward ($5,181M ending balance in FY25; $6,089M accrued at Q2 2026), and Top 3 U.S. wholesaler concentration (McKesson 37%, Cencora 30%, Cardinal Health 12% of FY25 revenues); (6) R&D Cost Structure ($1,764M GAAP R&D in Q2 2026 split between Personnel/Infrastructure $1,146M and Clinical Studies $618M; $11,183M Acquired IPR&D in Q2 2026 from Arcellx/Tubulis/Ouro acquisitions), biotech ownership stakes (Arcus 32.0%, Galapagos 25.1%, Assembly 29.5%), and standalone financial & Gilead-collaboration KPIs of listed oncology affiliate Arcus Biosciences, Inc. (NYSE: RCUS, CIK 0001724521); and (7) GAAP vs. Non-GAAP Reconciliations (86.9% Non-GAAP gross margin in Q2 2026; $8.15 Non-GAAP diluted EPS in FY25; $3,432M Free Cash Flow in Q2 2026).
  • Groups 8–12 cover: (8) Inventories by production stage ($2,521M total at Q2 2026: Raw Materials $1,226M, WIP $656M, Finished Goods $639M), PP&E by geography ($6,073M net at Q2 2026), Goodwill ($8,763M) & Drug Intangible Assets ($16,442M net at Q2 2026: Trodelvy $9,779M, Sofosbuvir $1,512M, Yescarta $2,665M, Hepcludex $753M, Bulevirtide IPR&D $300M, plus 5-year future amortization schedule), and Operating Leases ($1,552M ROU assets at Q2 2026); (9) Level 3 Contingent Consideration ($425M at Q2 2026), Litigation Accrual Reserve ($153M at Q2 2026 & TDF/TAF product liability plaintiff counts), and Restructuring; (10) Debt & 5-Year Maturity Schedule ($22,201M noncurrent long-term debt at Q2 2026), Capital Return ($1,030M dividends / $0.82 per share and $376M buybacks in Q2 2026), Stock-Based Compensation by P&L line & award type ($1,039M in FY25), and Income Taxes (DTA/DTL breakdown & UTB rollforward $1,128M at FY25); (11) Global Workforce (~17,000 employees, $200M 401(k) match, $406M deferred compensation plan in FY25), CEO Pay Ratio (119:1 / $238,979 median employee in FY25), Workplace Safety (62 recordable injuries / 0.36 TRIR per 200K hours in FY25), and 9-year Environmental Sustainability inventory (50,391 mt CO2e Scope 1+2 market-based GHG, 1,355,943 mt CO2e Scope 3 GHG, 424,797 MWh energy with 190,154 MWh renewable, 526 ML water withdrawal, 6,230 mt nonhazardous & 3,742 mt hazardous waste in FY25); and (12) U.S. Pharmaceutical & Healthcare FRED Benchmarks & Core Financial Statements (DB).
  • No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics; bound disclosures such as 'more than 52%' or 'over 40%' are excluded from table cells). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.

Dữ liệu cập nhật 2026-10-29.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Consolidated Revenue Architecture, Base Business (Ex-Veklury) & Geographic Disaggregation

HIV Franchise — Treatment & Prevention (PrEP) Portfolio by Brand × Geography

Liver Disease Franchise (HCV, HBV/HDV, PBC) & Veklury (Remdesivir) by Brand × Geography

Oncology (Kite Cell Therapy & Trodelvy ADC) & Other Products Portfolio by Brand × Geography

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Gilead Sciences

See a number that looks wrong?